hit counter
Research · Intelligence · Integrity
LONGEVITY METABOLIC HEALTH

New ACOG Menopause Guidance: Hormones & Hot Flash Relief

Disruptive menopause symptoms deserve treatment. That is the practical message behind renewed attention to hormone therapy and an updated American College of Obstetricians and Gynecologists (ACOG) guideline covering hot flashes, sleep disruption, and mood symptoms. Effective care can include hormonal and nonhormonal treatments, chosen around a woman’s symptoms, health history, and preferences. The update is an opportunity to revisit care with better information—not a reason for everyone to start hormones. [1] [2]

For women trying to work, exercise, sleep, and feel like themselves, this conversation reaches well beyond an occasional hot flash. A treatment discussion can begin with a straightforward question: Which symptoms are interfering with my life, and what can we do about them?

What is new in menopause care?

ACOG’s new clinical practice guideline evaluates drug and nondrug approaches to menopause-related vasomotor symptoms—the medical term for hot flashes and night sweats—as well as sleep and mood symptoms. It covers both perimenopause and postmenopause, including spontaneous menopause and induced menopause at or beyond age 40. Its recommendations use a structured assessment of evidence quality; some clinical guidance is provided as good practice points where evidence is insufficient for a formal recommendation. [1]

A separate regulatory change is also shaping the discussion. The FDA began revising hormone-therapy boxed warnings in November 2025 and approved labeling changes for an initial six products in February 2026. On October 30, 2026, federal officials announced updated labeling for three additional estradiol patch products. These changes remove specified cardiovascular, breast-cancer, and probable-dementia statements from the boxed-warning section for the affected products. A labeling change does not eliminate treatment risks or make every hormone product interchangeable. [3] [4]

Is hormone therapy still the most effective treatment for hot flashes?

Yes. Systemic menopausal hormone therapy remains the most effective treatment for hot flashes and night sweats. “Systemic” means hormones enter the circulation and act throughout the body. Options include pills, patches, gels, and sprays. For many eligible women with bothersome symptoms, it is a leading treatment to discuss. [2] [5]

The treatment plan also depends on whether a woman has a uterus. With systemic estrogen, a progestogen is generally needed to protect the uterine lining; certain alternative combinations provide protection differently. This is one reason the decision involves more than choosing an estrogen dose. Low-dose vaginal estrogen serves a different purpose: it treats local symptoms such as vaginal dryness and is not a substitute for systemic treatment of hot flashes. [5]

Why do age and time since menopause matter?

The balance of benefit and risk is generally more favorable for symptomatic women younger than 60 or within 10 years of menopause onset who have no contraindications. Starting later can carry greater absolute risks, including blood clots, stroke, and coronary heart disease. This timing framework supports an individual assessment; it is not a universal eligibility rule. Formulation, dose, route, duration, and medical history all matter. [2]

A history of breast or endometrial cancer, stroke, heart attack, blood clots, or liver disease can change whether systemic hormone therapy is appropriate. The right conversation includes those risks alongside symptom burden and treatment goals, with periodic reassessment rather than an assumption that the original plan should continue indefinitely. [5]

What if a woman cannot—or prefers not to—use hormones?

Nonhormonal options include selected antidepressants, gabapentin, and medicines that target neurokinin signaling involved in temperature regulation. Fezolinetant, sold as Veozah, blocks the neurokinin-3 receptor. Elinzanetant, sold as Lynkuet and approved by the FDA in October 2025, offers another prescription option for moderate to severe hot flashes. These medicines create additional treatment choices without replacing estrogen. [6] [7] [8]

Nonhormonal does not mean risk-free. Fezolinetant carries a boxed warning for rare but serious liver injury and requires liver testing before treatment and during follow-up. Elinzanetant has its own precautions, including liver testing and possible daytime impairment or sleepiness. Drug interactions and monitoring requirements should be reviewed for the specific medication. [7] [9]

Which approach addresses which problem?

Approach Main role Key consideration
Systemic hormone therapy Most effective treatment for hot flashes and night sweats. Requires an individual risk assessment and appropriate protection of the uterine lining.
Low-dose vaginal estrogen Treats local vaginal symptoms, including dryness. Does not treat hot flashes throughout the body.
Neurokinin-targeting medicines Provide nonhormonal treatment for hot flashes. Have medication-specific precautions and monitoring requirements.
Selected antidepressants or gabapentin Offer additional nonhormonal treatment options. Selection depends on symptoms, other medications, and tolerability.
Cognitive behavioral therapy for insomnia Improves sleep through structured behavioral strategies. Can complement treatment of nighttime symptoms.

Treatment options have different goals; this is not a ranking.

Sources for comparison: ACOG, FDA, and National Institute on Aging. [5] [6] [7] [8] [9] [10]

Why sleep deserves its own treatment conversation

Night sweats can repeatedly interrupt sleep, but not every sleep problem during midlife has the same cause. Persistent insomnia may need its own assessment and treatment. The National Institute on Aging identifies cognitive behavioral therapy for insomnia as an approach that can improve sleep in women with menopausal symptoms. Sleep habits and treatment of nighttime hot flashes can also be part of the plan. [10]

A useful symptom diary records nighttime awakenings, whether sweating occurred, daytime fatigue, and the impact on normal activities. That gives a clinician more to work with than “I’m tired all the time.” Mood changes deserve the same attention rather than being automatically attributed to hormones.

What does this mean for metabolic health and longevity?

Menopause is a useful time to review bone and cardiovascular health. Bone loss accelerates after menopause, and heart-disease risk rises. Exercise, smoking cessation, appropriate nutrition, and routine preventive care remain central. Hormone therapy can help prevent bone loss, but it is not recommended to prevent heart disease or stroke. [11]

For PharmaKinetics readers, the practical connection is that symptom care and long-term health planning belong in the same conversation. Feeling and sleeping better may make healthy routines easier to sustain; that is a practical inference, not proof that symptom treatment extends lifespan. This guideline does not establish hormone therapy as an anti-aging treatment, a weight-loss drug, or a way to reverse biological age.

What should women ask at their next appointment?

Bring a short symptom record and ask: Am I in perimenopause or menopause? Which symptoms are likely related? Am I a candidate for systemic hormones, and would I need uterine protection? If I prefer a nonhormonal option, which treatment fits my symptoms and other medications? What monitoring will I need, and when should we reassess whether it is working?

The goal is a treatment plan with a clear purpose: fewer disruptive symptoms, better daily function, and follow-up that checks both benefit and risk. Women have evidence-based options, and the choice can evolve as their needs change.

Sources and references

  1. ACOG. Management of Menopause-Related Vasomotor, Sleep, and Mood Symptoms. Obstetrics & Gynecology. 2026;148(5):e345–e369. doi:10.1097/AOG.0000000000006428. November issue; update reported in October.
  2. The North American Menopause Society. The 2022 hormone therapy position statement.
  3. FDA. Labeling changes to menopausal hormone therapy products. February 12, 2026.
  4. HHS/FDA. Menopause hormone-therapy labeling and access update. October 30, 2026.
  5. ACOG. Hormone Therapy for Menopause.
  6. ACOG. What can I do to help with hot flashes?
  7. FDA. Veozah: rare serious liver injury and monitoring requirements.
  8. FDA. Drug Trials Snapshots: Lynkuet.
  9. FDA. Lynkuet prescribing information.
  10. National Institute on Aging. Sleep Problems and Menopause: What Can I Do?
  11. Office on Women’s Health. Menopause and your health. Updated October 19, 2026.